Newsgroup: it.economia.borsa
Titolo: XYOTAX(TM) Significantly Prolongs Survival Among Women With Advanced Lung Cancer

      XYOTAX(TM) Significantly Prolongs Survival Among Women With Advanced
Lung Cancer
Third Clinical Trial Provides Further Evidence of Survival Advantage in
Women
                   Reported in the STELLAR 3 and 4 StudiesNEW YORK, Sept. 27
/PRNewswire-FirstCall/ -- At a presentation at the UBS Global Life Sciences
Conference, Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX: CTIC)
presented new results from a recently completed phase II clinical trial of
XYOTAX in the first-line treatment of men and women with advanced non-small
cell lung cancer (NSCLC). In that single arm study, known as PGT202, the 35
women who received XYOTAX plus carboplatin had a 36 percent probability of
living at least 1 year compared to only 16 percent in the 39 men receiving
the same regimen. A pooled analysis of XYOTAX treated patients from STELLAR
3, STELLAR 4 and the PGT202 trial demonstrated a statistically significant
(p=0.004) survival advantage for women treated when compared to men, with
women having a 39 percent probability of surviving at least 1 year compared
to 25 percent of men (HR =1.37, log rank p = 0.014 N = 463 patients). The
Company previously reported that in a combined analysis of STELLAR 3 and 4,
women treated with XYOTAX survived significantly longer than women treated
on the standard chemotherapy control arms of these studies.
      "To the best of our knowledge this is the first time a drug therapy
for advanced lung cancer has consistently demonstrated such a strong
survival advantage for women compared to men or compared to women randomized
to treatment with standard chemotherapy," noted Jack W. Singer, M.D., Chief
Medical Officer at CTI. "We are currently evaluating the effect of estrogen
on the metabolism of XYOTAX in normal and cancerous tissues to provide
mechanistic support for these important clinical results."
      In August, CTI outlined its plans to file a New Drug Application (NDA)
in the United States and a Marketing Authorization Application (MAA) in
Europe in 2006 based on the results of its Stellar 3 and 4 trials.
      About Lung Cancer in Women
      Several studies have indicated that compared to men, women who smoke
are more likely to develop lung cancer at a younger age and at lower levels
of exposure to cigarette smoke. Non-smoking women are at higher risk for
developing lung cancer than non-smoking men. Research has focused on the
influence of genetic differences between men and women and on the role of
estrogen to explain these findings. Estrogen enhances the effects of
carcinogens in the environment and in smoke, possibly leading to a higher
risk for NSCLC and once it occurs, appears to enhance its development. Since
women have higher levels of estrogen than men, and younger women have higher
levels of estrogen than older women, this may in part be responsible for
their higher risk for NSCLC. Developing therapies that are favorably
influenced by estrogen may provide a gender-targeted therapeutic approach to
the treatment of NSCLC.
      About Lung Cancer
      According to the American Cancer Society, lung cancer is the leading
cause of cancer death among both men and women and results in more deaths
per year than colorectal, breast, prostate, liver, and kidney cancers
combined. Nearly 60 percent of people with lung cancer die within one year
of their diagnosis and nearly 75 percent die within 2 years; figures which
have not improved in 10 years. Lung cancer is expected to kill nearly twice
as many women as breast cancer this year.
      About XYOTAX
      XYOTAX (paclitaxel poliglumex) is a pharmaceutical that links
paclitaxel, the active ingredient in Taxol(R), to a biodegradable
polyglutamate polymer, which results in a new chemical entity. Blood vessels
in tumor tissue, unlike blood vessels in normal tissue, are porous to
molecules like polyglutamate. Based on preclinical studies, it appears that
XYOTAX is preferentially trapped in the tumor blood vessels allowing
significantly more of the dose of chemotherapy to localize in the tumor.
      About Cell Therapeutics, Inc.
      Headquartered in Seattle, CTI is a biopharmaceutical company committed
to developing an integrated portfolio of oncology products aimed at making
cancer more treatable. For additional information, please visit
www.cticseattle.com
.
      This press release includes forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect actual future results. Specifically, the risks and
uncertainties that could affect the development of XYOTAX include risks
associated with preclinical and clinical developments in the
biopharmaceutical industry in general and with XYOTAX in particular
including, without limitation, the potential failure of XYOTAX to prove safe
and effective or to be approved for use in non-small cell lung cancer, risks
that the results of any single STELLAR trial or the body of data from all 3
STELLAR trials will not be sufficient for approval of XYOTAX for the
treatment of lung cancer, risks that our submissions will not be accepted by
regulatory agencies or that any confirmatory trials will commence and will
confirm a gender effect in women with lung cancer, determinations by
regulatory, patent and administrative governmental authorities, competitive
factors, technological developments, costs of developing, producing and
selling XYOTAX, and the risk factors listed or described from time to time
in the Company's filings with the Securities and Exchange Commission
including, without limitation, the Company's most recent filings on Forms
10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly disclaims
any such obligation to) update or alter its forward-looking statements
whether as a result of new information, future events, or otherwise.

 cell lung cancer (NSCLC). 
Ecco, inizio da qui.
Innanzi tutto tu sei l'unico serio interlocutore che può parlare di 
cell, e questo ti và riconosciuto.
Se ben ricordi, dissi che l'unico miracolo possibile per Cell sarebbe 
stato lo xyotax.
Attenzione, però: presentare dei risultati ad una conference NON è
ottenere l'autorizzazione per il farmaco, per altro già negata almeno 
una volta.
Resto della mia opinione, dunque, ma faccio i complimenti a chi ha 
realmente guadagnato (inutile vantarsi virtualmente, la nostra coscienza 
sà tutto).
Auguri, Mascheroni
Apuo

 Apuo
grazie per gli auguri
io rispetto le opinioni di tutti, se motivate, soprattutto quelle
contrarie alle mie, perchè servono a farmi riflettere
mi infastidiscono solo le pirlate

 the same regimen.
...
Lo Xyotax e' un farmaco che prolunga l agonia?
Tutto qui?

 Tutto qui?
c'č anche il cianuro per chi vuole interrompere immediatamente


...detto tra noi non č una vera news ma solo una vecchia news rimessa li per
l'occorrenza quando avevano voglia di ripartire ;-)
Che lo xyotax avesse maggior beneficio per le donne lo si sapeva sin da
maggio scorso.

 c'è anche il cianuro per chi vuole interrompere immediatamente
C'e' il modo di ridurre drasticamente la probabilita' di contrarre malattie 
del genere...ma evidentemente conviene piu' promuovere un farmaco che uno 
stile di vita corretto.